Biogen Initiates Randomized Trial of Lumiliximab for Advanced CLL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 3
Volume 16
Issue 3

Biogen Initiates Randomized Trial of Lumiliximab for Advanced CLL

CAMBRIDGE, Massachusetts—Biogen Idec has initiated a randomized, multicenter, registration trial, known as LUCID, of its anti-CD23 monoclonal antibody lumiliximab in combination with fludarabine, cyclophosphamide, and rituximab (FCR) vs FCR alone for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The antibody was also granted Fast Track and Orphan Drug designation by FDA. In a phase I/II trial reported at the 2006 ASH Annual Meeting, the addition of lumiliximab to the FCR regimen resulted in a 52% complete response rate among CLL patients with progressive disease, the company said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
2 experts are featured in this series.
Related Content